

IN THE CLAIMS

1-22. (previously canceled)

23-45. (canceled herein)

46. (currently amended) A product suitable for delivering a pharmaceutical aerosol formulation comprising,

(a) an aerosol canister comprising a container closed with a metering valve, said container comprising a pharmaceutical suspension aerosol formulation substantially free of surfactant, and which consists of salbutamol sulphate, ethanol in an amount of 10% w/w to 15% w/w, and 1,1,1,2-tetrafluoroethane, wherein salbutamol sulphate is substantially completely insoluble in the 1,1,1,2-tetrafluoroethane, and

(b) an actuator with a spray orifice aperture of from 100 to 300 microns.

47. (currently amended) A product suitable for delivering a pharmaceutical aerosol formulation comprising,

(a) an aerosol canister comprising a container closed with a metering valve, said container comprising a pharmaceutical suspension aerosol formulation substantially free of surfactant, and which consists essentially of salbutamol sulphate, ethanol in an amount of 10% w/w to 15% w/w, and 1,1,1,2-tetrafluoroethane, wherein the salbutamol sulphate is substantially completely insoluble in the 1,1,1,2-tetrafluoroethane, and

(b) an actuator with a spray orifice aperture of from 100 to 300 microns.

48. (new) The product of claim 46, wherein the aerosol formulation contains ethanol in the amount of 11.4% w/w.

49. (new) The product of claim 46, wherein the aerosol formulation contains salbutamol sulfate in the amount of 0.4% w/w.

50. (new) The product of claim 46, wherein the aerosol formulation contains 1,1,1,2-tetrafluoroethane in the amount of 88.2% w/w.

51. (new) The product of claim 46, wherein the aerosol formulation contains salbutamol sulphate in the amount of 0.4% w/w, ethanol in the amount of 11.4% w/w, and 1,1,1,2-tetrafluoroethane in the amount of 88.2% w/w.

52. (new) The product of claim 47, wherein the aerosol formulation contains ethanol in the amount of 11.4% w/w.

53. (new) The product of claim 47, wherein the aerosol formulation contains salbutamol sulfate in the amount of 0.4% w/w.

54. (new) The product of claim 47, wherein the aerosol formulation contains 1,1,1,2-tetrafluoroethane in the amount of 88.2% w/w.

55. (new) The product of claim 47, wherein the aerosol formulation contains salbutamol sulphate in the amount of 0.4% w/w, ethanol in the amount of 11.4% w/w, and 1,1,1,2-tetrafluoroethane in the amount of 88.2% w/w.

56. (new) A product suitable for delivering a pharmaceutical aerosol formulation comprising,

(a) an aerosol canister comprising a container closed with a metering valve, said container comprising a pharmaceutical suspension aerosol formulation substantially free of surfactant, and which consists of salbutamol sulphate, ethanol in an amount of 10% w/w to 15% w/w, and 1,1,1,2-tetrafluoroethane, wherein salbutamol sulphate is substantially completely insoluble in the 1,1,1,2-tetrafluoroethane, and

(b) an actuator with a spray orifice aperture of from 150 to 250 microns.

57. (new) The product of claim 56, wherein the aerosol formulation contains ethanol in the amount of 11.4% w/w.

58. (new) The product of claim 56, wherein the aerosol formulation contains salbutamol sulfate in the amount of 0.4% w/w.

59. (new) The product of claim 56, wherein the aerosol formulation contains 1,1,1,2-tetrafluoroethane in the amount of 88.2% w/w.

60. (new) The product of claim 56, wherein the aerosol formulation contains salbutamol sulphate in the amount of 0.4% w/w, ethanol in the amount of 11.4% w/w, and 1,1,1,2-tetrafluoroethane in the amount of 88.2% w/w.

61. (new) A product suitable for delivering a pharmaceutical aerosol formulation comprising,

(a) an aerosol canister comprising a container closed with a metering valve, said container comprising a pharmaceutical suspension aerosol formulation substantially free of surfactant, and

which consists essentially of salbutamol sulphate, ethanol in an amount of 10% w/w to 15% w/w, and 1,1,1,2-tetrafluoroethane, wherein the salbutamol sulphate is substantially completely insoluble in the 1,1,1,2-tetrafluoroethane, and

(b) an actuator with a spray orifice aperture of from 150 to 250 microns.

62. (new) The product of claim 61, wherein the aerosol formulation contains ethanol in the amount of 11.4% w/w.

63. (new) The product of claim 61, wherein the aerosol formulation contains salbutamol sulfate in the amount of 0.4% w/w.

64. (new) The product of claim 61, wherein the aerosol formulation contains 1,1,1,2-tetrafluoroethane in the amount of 88.2% w/w.

65. (new) The product of claim 61, wherein the aerosol formulation contains salbutamol sulphate in the amount of 0.4% w/w, ethanol in the amount of 11.4% w/w, and 1,1,1,2-tetrafluoroethane in the amount of 88.2% w/w.